近日，天士力自主研发的同种异体脂肪间充质基质细胞注射液（NR-20201）获国家药品监督管理局药品审评中心（CDE）批准开展临床，治疗急性缺血性脑卒中。这是CDE批准的国内首款间充质基质细胞药的临床试验申请 ...

On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking ...

近期，国际学术期刊ACS Nano在线发表了石鹏教授团队以“Adhesion-assisted antioxidant-engineered mesenchymal stromal cells for enhanced cardiac repair ...

Scientists have uncovered a hidden driver of ovarian cancer—high-risk mesenchymal stem cells lurking in the fallopian tubes.

2012年，美国FDA拒绝了Osiris的骨髓来源药物Prochymal的上市申请。其宣称的干细胞修复机制与其临床数据脱节，且缺乏可验证的效力测定方法支持。这一结论在Osiris的2012年SEC文件与美国FDA 2017年细胞治疗指南中均有迹可循。这一失败揭示了关键问题：缺乏有效的效力测定、未见明确的作用机制以及未证实MSC在体内发挥"干细胞"的分化能力。

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

Researchers at the University of Pittsburgh have identified a novel trigger for a deadly form of ovarian cancer: a subset of ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast Limited announced that its CEO, Silviu Itescu, will ...

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive ...

The intrinsic factor of cell senescence, PCBP2, was identified by unlabeled quantitative proteomics, and its biological role in in vitro replication senescence of human bone marrow mesenchymal stromal ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P ...